Jump to content

New Genedata Screener 19.0 Further Accelerates Biotherapeutics R&D

Smart workflow automation and fit-for-purpose, big data visualizations enable fast, functional characterization of tens of thousands of candidate molecules.

April 26, 2022
Basel, Switzerland

Genedata, a leading provider of enterprise software solutions for biopharma R&D, today announced the availability of Genedata Screener® 19.0, the latest version of its award-winning data management and analysis platform for all bioassays in biotherapeutics R&D. Based on a deep understanding of experimental workflows, Genedata Screener automates complex data analytical workflows and enables efficient decision making across the organization. Genedata Screener 19.0  also accelerates the in-parallel characterization of tens of thousands of molecules, enables FAIR data compliance, and empowers R&D organizations to quickly scale up high-throughput analysis of Epitope Binning, Flow Cytometry, Surface Plasmon Resonance (SPR), and Thermal Shift Assays (TSA). 

Smart Automation and Intuitive Visualizations Save Time & Improve Decision Making
New automation features in Genedata Screener 19.0 streamline and enable up-scaling of typical assays in biotherapeutics research and development. Interactive big data visualizations provide scientists with a flexible and fast process to review, interpret, annotate, and sign-off on large result sets, including side-by-side comparisons of all cell types analyzed in single experiments. Specific assay applications include:
•    Cell panel, primary cell, and QIFIKIT® bead assays in high-throughput flow cytometry, including data capture, traceability, and provenance from raw data to final results at small and large-scale, with flexible gating adjustment across multiple cell types.
•    High-throughput epitope binning assays, including the analyses across hundreds of thousands of antibody combinations, hereby streamlining the selection of the most promising antibody candidates early in biotherapeutics discovery.
•    Thermal shift assays for determination of binding and stability of large multi-domain proteins as well as in a cellular context, using emerging technologies such as CETSA, now quantifying and visualizing single or multiple melting temperatures for tens of thousands of samples.
•    SPR-based assays, combining automated processing with an efficient visual sensorgram review and annotation across thousands of samples. 

“Genedata Screener is used by the world’s top 50 pharma companies and a rapidly growing network of innovative biotechs and CROs because it is the most comprehensive bioassay analysis platform for biotherapeutics research and development,” said Othmar Pfannes, Ph.D., CEO of Genedata. ”With each new release, we raise the bar on lab efficiency, ROI, and innovation—all aimed at accelerating novel drug discovery.“ 

About Genedata

Genedata transforms data into intelligence with innovative software solutions that incorporate extensive biopharma R&D domain knowledge. Multinational biopharmaceutical organizations and cutting-edge biotechs around the globe rely on Genedata to digitalize and automate data-rich and complex R&D processes. From early discovery all the way to the clinic, Genedata solutions help maximize the ROI in R&D expenditure. Founded in 1997, Genedata is headquartered in Basel, Switzerland with additional offices in Boston, London, Munich, San Francisco, Singapore, and Tokyo.
LinkedIn | Twitter | YouTube


Allison Kurz
Public Relations


The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

All product and service names mentioned are the trademarks of their respective companies.

With each new release, we raise the bar on lab efficiency, ROI, and innovation — all aimed at accelerating novel drug discovery.